| # | Drug | Count |
|---|---|---|
| 0 | TOCILIZUMAB | 78 |
| 1 | ANAKINRA | 76 |
| 2 | CANAKINUMAB | 66 |
| 3 | IBUPROFEN | 56 |
| 4 | SODIUM CHLORIDE | 53 |
| 5 | SODIUM CHLORIDE TABLET | 52 |
| 6 | SODIUM CHLORIDE TABLETS | 52 |
| 7 | CYCLOSPORINE | 51 |
| 8 | ACETAMINOPHEN | 50 |
| 9 | CYCLOPHOSPHAMIDE | 49 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PRILOCAINE HYDROCHLORIDE | 1 | 0.0062 |
| 1 | CANAKINUMAB | 66 | 0.0060 |
| 2 | CLEMASTINE FUMARATE | 7 | 0.0050 |
| 3 | SILTUXIMAB | 3 | 0.0046 |
| 4 | ANAKINRA | 76 | 0.0045 |
| 5 | EMAPALUMAB-LZSG | 1 | 0.0042 |
| 6 | LIFILEUCEL | 1 | 0.0035 |
| 7 | SALSALATE | 3 | 0.0032 |
| 8 | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS, POTASSIUM PHOSPHATE, MONOBASIC, AND SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 1 | 0.0021 |
| 9 | GLOFITAMAB | 5 | 0.0018 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 136 |
| 1 | Nonsteroidal Anti-inflammatory Drug [EPC] | 97 |
| 2 | Interleukin-6 Receptor Antagonist [EPC] | 78 |
| 3 | Interleukin-1 Receptor Antagonist [EPC] | 76 |
| 4 | Osmotic Laxative [EPC] | 65 |
| 5 | Janus Kinase Inhibitor [EPC] | 56 |
| 6 | Platinum-based Drug [EPC] | 56 |
| 7 | Kinase Inhibitor [EPC] | 54 |
| 8 | Nucleoside Metabolic Inhibitor [EPC] | 54 |
| 9 | Alkylating Drug [EPC] | 53 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-6 Antagonist [EPC] | 3 | 0.0046 |
| 1 | Interleukin-1 Receptor Antagonist [EPC] | 76 | 0.0045 |
| 2 | Interferon gamma Blocker [EPC] | 1 | 0.0042 |
| 3 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 6 | 0.0015 |
| 4 | Lipid-based Polyene Antifungal [EPC] | 14 | 0.0011 |
| 5 | Macrolide Antibacterial [EPC] | 1 | 0.0010 |
| 6 | Surfactant [EPC] | 1 | 0.0009 |
| 7 | Enzyme Stabilizer [EPC] | 1 | 0.0009 |
| 8 | CD19-directed Chimeric Antigen Receptor [EPC] | 8 | 0.0008 |
| 9 | Interleukin-6 Receptor Antagonist [EPC] | 78 | 0.0006 |